Skip to content

The clinical efficacy and safety of absorbable fluid gelatin in percutaneous transforaminal endoscopic surgery for lumbar spinal stenosis: a randomized controlled study

The clinical efficacy of absorbable fluid gelatin in the treatment of lumbar spinal stenosis in percutaneous transforaminal endoscopic.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077538
Enrollment
Unknown
Registered
2023-11-11
Start date
2023-11-13
Completion date
Unknown
Last updated
2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Spinal Stenosis

Interventions

Sponsors

Weifang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Single level lumbar spinal stenosis with complete history, physical examination and imaging and definite diagnosis, and no significant improvement after 3 months of conservative treatment; 2) Age 20-80 years old; 3) Sign the informed consent form and be able to accurately read or understand the informed consent form and follow-up questionnaires when accompanied by family members; 4) Able to agree to and fully adhere to clinical protocols and willing to adhere to follow-up schedules and requirements.

Exclusion criteria

Exclusion criteria: 1) spinal stenosis caused by fracture, tumor and infection; 2) History of spinal surgery; 3) Patients who take anticoagulants or have a history of thrombosis, or are at high risk of thrombosis, including atrial fibrillation, pacemaker and stent implantation; 4) Clear allergy to fluid gelatin or contraindication; 5) Patients who are participating in other clinical trials; 6) Systemic infections such as lung infection and urinary tract infection were not controlled before operation; 7) Suffering from mental and psychological disorders such as schizophrenia, depression, history of chronic analgesic use, alcoholism, opioid dependence; 8) Other situations considered by the researchers to be inappropriate for this study.

Design outcomes

Primary

MeasureTime frame
Perioperative blood loss;Hemostasis time;

Secondary

MeasureTime frame
Thrombus event;immunological rejection event;anaphylactic reaction event;hematoma event;Blood index;Operation time;Hospital stay;hospitalization expenses;

Countries

China

Contacts

Public ContactWeiqiang Liu

Weifang People's Hospital

liuwqspine@126.com+86 187 6510 9800

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026